Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Chugai Pharmaceutical Co., Ltd.    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD.

(4519)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Tokyo Stock Exchange
10/19/2020 10/20/2020 10/21/2020 10/22/2020 10/23/2020 Date
4393 4353 4305 4156 4281 Last
1321900 1301900 1591700 1581700 2761200 Volume
+1.71% -0.91% -1.10% -3.46% +3.01% Change
Financials
Sales 2020 760 B 7 253 M 7 253 M
Net income 2020 211 B 2 018 M 2 018 M
Net cash position 2020 403 B 3 844 M 3 844 M
P/E ratio 2020 33,2x
Yield 2020 1,19%
Sales 2021 828 B 7 904 M 7 904 M
Net income 2021 246 B 2 347 M 2 347 M
Net cash position 2021 496 B 4 738 M 4 738 M
P/E ratio 2021 28,2x
Yield 2021 1,54%
Capitalization 7 037 B 67 163 M 67 191 M
EV / Sales 2020 8,73x
EV / Sales 2021 7,90x
Nbr of Employees 7 394
Free-Float 37,7%
More Financials
Company
Chugai Pharmaceutical Co. Ltd specializes in the research, development, manufacturing and marketing of drugs especially for cancers (40.8% of net sales), bones and joints diseases treatment (18.4%), and kidney diseases (5.9%). Net sales are distributed geographically as follows: Japan (74,3%), Switzerland (22,8%) and other (2,9%). 
Sector
Pharmaceuticals
Calendar
12/29
More about the company
Notations Surperformance© of Chugai Pharmaceutical Co., Ltd.
Trading Rating : Investor Rating :
More Ratings
All news about CHUGAI PHARMACEUTICAL CO., LTD.
10/23CHUGAI PHARMACEUTICAL : Announces 2020 3rd Quarter Results
AQ
10/22Japan stocks end lower as firmer yen, U.S. political uncertainty weigh
RE
10/22Japanese shares fall on rising yen, U.S. political uncertainty
RE
10/21PTC Therapeutics Says Evrysdi Approved in Brazil, Japan NDA Filed
DJ
10/20Chugai and Welby Launch a Treatment Support Personal Health Record Service fo..
AQ
10/19CHUGAI PHARMACEUTICAL CO., LTD. : quaterly earnings release
10/16CHUGAI PHARMACEUTICAL : Files a New Drug Application for Risdiplam as the First ..
AQ
10/07CHUGAI PHARMACEUTICAL : enters into a License Agreement for 's Antibody Engineer..
AQ
10/05CHUGAI PHARMACEUTICAL : Files for Expanded Use of FoundationOne CDx Cancer Genom..
AQ
10/05CHUGAI PHARMACEUTICAL : Files for Expanded Use of FoundationOne CDx Cancer Genom..
AQ
09/28CHUGAI PHARMACEUTICAL : Obtains Approval for Additional Indication of Tecentriq ..
AQ
09/10Chugai and Takeda to Join a Clinical Collaboration for Global Phase III Studi..
AQ
09/10Chugai and NTT DATA Complete Demonstration of AI-based Clinical Trial Efficie..
AQ
09/10CHUGAI PHARMACEUTICAL : New Data of Chugai's Enspryng (Satralizumab) on Risk and..
BU
09/02CHUGAI PHARMACEUTICAL : Introduces LINE WORKS by WORKS MOBILE Japan for 2,400 Em..
AQ
More news
News in other languages on CHUGAI PHARMACEUTICAL CO., LTD.
10/19CHUGAI PHARMACEUTICAL CO., LTD. : Veröffentlichung des Quartalsergebnisses
10/19CHUGAI PHARMACEUTICAL CO., LTD. : publication des résultats trimestriels
10/16TOUR DU MONDE DES INDICES : De l’équilibrisme à l’or bleu
10/15ROCHE : Chugai dépose une demande d'homologation pour Risdiplam
09/25ROCHE : extension d'homologation pour Tecentriq et Avastin au Japon
More news
Stock Trading Strategies
CHUGAI PHARMACEUTICAL CO., LTD. - 05/18
The trend should regain control
BUY
More Stock Trading Analysis
Chart CHUGAI PHARMACEUTICAL CO., LTD.
Duration : Period :
Chugai Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 4 939,75 JPY
Last Close Price 4 281,00 JPY
Spread / Highest target 63,5%
Spread / Average Target 15,4%
Spread / Lowest Target -13,6%
EPS Revisions
Managers
NameTitle
Tatsuro Kosaka Chairman & Chief Executive Officer
Osamu Okuda President, COO & Representative Director
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CHUGAI PHARMACEUTICAL CO., LTD.27.41%67 163
JOHNSON & JOHNSON-0.43%382 391
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-2.55%212 162
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-16.78%185 999